A detailed history of Virtus ETF Advisers LLC transactions in Allogene Therapeutics, Inc. stock. As of the latest transaction made, Virtus ETF Advisers LLC holds 36,285 shares of ALLO stock, worth $82,366. This represents 0.05% of its overall portfolio holdings.

Number of Shares
36,285
Previous 35,640 1.81%
Holding current value
$82,366
Previous $83,000 21.69%
% of portfolio
0.05%
Previous 0.04%

Shares

22 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$2.08 - $3.5 $1,341 - $2,257
645 Added 1.81%
36,285 $101,000
Q2 2024

Aug 14, 2024

BUY
$2.23 - $4.38 $8,190 - $16,087
3,673 Added 11.49%
35,640 $83,000
Q1 2024

May 15, 2024

SELL
$2.92 - $5.63 $6,412 - $12,363
-2,196 Reduced 6.43%
31,967 $142,000
Q4 2023

Feb 15, 2024

BUY
$2.28 - $3.5 $32,667 - $50,148
14,328 Added 72.24%
34,163 $109,000
Q3 2023

Nov 07, 2023

SELL
$3.17 - $5.96 $6,270 - $11,788
-1,978 Reduced 9.07%
19,835 $62,000
Q2 2023

Aug 14, 2023

BUY
$4.53 - $6.74 $39,601 - $58,921
8,742 Added 66.88%
21,813 $108,000
Q1 2023

May 15, 2023

SELL
$4.92 - $8.21 $24,727 - $41,263
-5,026 Reduced 27.77%
13,071 $64,000
Q4 2022

Feb 14, 2023

BUY
$5.62 - $11.11 $37,288 - $73,714
6,635 Added 57.89%
18,097 $113,000
Q3 2022

Nov 14, 2022

BUY
$10.32 - $17.28 $815 - $1,365
79 Added 0.69%
11,462 $124,000
Q2 2022

Aug 12, 2022

BUY
$6.78 - $12.28 $3,627 - $6,569
535 Added 4.93%
11,383 $130,000
Q1 2022

May 16, 2022

SELL
$7.65 - $15.29 $4,888 - $9,770
-639 Reduced 5.56%
10,848 $99,000
Q4 2021

Feb 14, 2022

BUY
$13.13 - $24.52 $40,808 - $76,208
3,108 Added 37.09%
11,487 $171,000
Q3 2021

Nov 15, 2021

SELL
$21.01 - $27.64 $9,202 - $12,106
-438 Reduced 4.97%
8,379 $215,000
Q2 2021

Aug 10, 2021

SELL
$23.49 - $35.8 $44,724 - $68,163
-1,904 Reduced 17.76%
8,817 $230,000
Q1 2021

May 17, 2021

BUY
$25.79 - $39.02 $4,771 - $7,218
185 Added 1.76%
10,721 $378,000
Q4 2020

Feb 12, 2021

BUY
$25.24 - $43.45 $73,827 - $127,091
2,925 Added 38.43%
10,536 $266,000
Q3 2020

Nov 13, 2020

SELL
$32.38 - $44.96 $33,642 - $46,713
-1,039 Reduced 12.01%
7,611 $287,000
Q2 2020

Aug 05, 2020

SELL
$18.39 - $54.04 $85,127 - $250,151
-4,629 Reduced 34.86%
8,650 $370,000
Q1 2020

May 14, 2020

SELL
$18.22 - $28.25 $35,255 - $54,663
-1,935 Reduced 12.72%
13,279 $258,000
Q4 2019

Feb 13, 2020

BUY
$24.82 - $31.4 $140,530 - $177,786
5,662 Added 59.28%
15,214 $395,000
Q3 2019

Nov 12, 2019

SELL
$26.11 - $32.99 $13,890 - $17,550
-532 Reduced 5.28%
9,552 $260,000
Q2 2019

Aug 13, 2019

BUY
$25.56 - $31.09 $257,747 - $313,511
10,084 New
10,084 $271,000

Others Institutions Holding ALLO

About Allogene Therapeutics, Inc.


  • Ticker ALLO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 143,807,008
  • Market Cap $326M
  • Description
  • Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult p...
More about ALLO
Track This Portfolio

Track Virtus ETF Advisers LLC Portfolio

Follow Virtus ETF Advisers LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Virtus ETF Advisers LLC, based on Form 13F filings with the SEC.

News

Stay updated on Virtus ETF Advisers LLC with notifications on news.